NVS NYSE
Novartis AG
1W: +2.1%
1M: +6.8%
3M: -1.3%
YTD: +13.2%
1Y: +20.3%
3Y: +76.1%
5Y: +123.7%
$156.86
+3.05 (+1.98%)
Weekly Expected Move ±3.4%
$141
$146
$151
$156
$162
Credit Risk of going bust: lower than 80% of companies Debt: 14.1% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $1.82 (down 99%), Novartis AG would be worth roughly what it owes.
Total debt $49.01B against a stock market value of $298.15B.
Distance to default 9.66 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $28.61B (short-term plus half of long-term), stock volatility 27.6%; Altman Z'' 2.30. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Total debt $49.01B against a stock market value of $298.15B.
Distance to default 9.66 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $28.61B (short-term plus half of long-term), stock volatility 27.6%; Altman Z'' 2.30. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
#6
of 19
Drug Manufacturers - General
Technical Signal Map
12 Bullish
1 Neutral
1 Bearish
NVS
$287B
Novartis AG
BULLISH
+75
ABBV
$505B
AbbVie Inc.
BULLISH
+100
JNJ
$636B
Johnson & Johnson
BULLISH
+91
SNY
$100B
Sanofi
BULLISH
+84
PFE
$171B
Pfizer Inc.
BULLISH
+82
RHHBF
$393B
Roche Holding AG
BULLISH
+75
GILD
$193B
Gilead Sciences, Inc.
BULLISH
+75
LLY
$1.2T
Eli Lilly and Company
BULLISH
+66
AMGN
$237B
Amgen Inc.
BULLISH
+66
GSK
$102B
GSK plc
BULLISH
+59
AZN
$266B
AstraZeneca PLC
LEAN BULL
+25
BMY
$126B
Bristol-Myers Squibb Company
LEAN BULL
+16
NONOF
$172B
Novo Nordisk A/S
NEUTRAL
-2
MRK
$358B
Merck & Co., Inc.
BEARISH
-68
Peer Comparison
| Symbol | Mkt Cap | P/E | ROE % | ROIC % | Net Mgn % | Rev Grw % | Piotroski | Signal | 1Y Ret % |
|---|---|---|---|---|---|---|---|---|---|
| NVS Novartis AG | $287B | 23.6 | 30.6 | 16.8 | 22.7 | 0.8 | 5 | BULLISH | 20.3 |
| ABBV AbbVie Inc. | $505B | 80.7 | -206.4 | 23.5 | 21.3 | 10.4 | 7 | BULLISH | 25.6 |
| JNJ Johnson & Johnson | $636B | 40.7 | 20.0 | 21.3 | 0.8 | 7.8 | 6 | BULLISH | 42.0 |
| SNY Sanofi | $100B | 23.0 | 5.7 | 6.4 | 2.8 | 13.4 | 6 | BULLISH | -18.9 |
| PFE Pfizer Inc. | $171B | 39.4 | 5.0 | 11.3 | -1.6 | -0.2 | 7 | BULLISH | 22.5 |
| RHHBF Roche Holding AG | $393B | 26.0 | 40.2 | 24.6 | 22.6 | 27.8 | 6 | BULLISH | 30.5 |
| GILD Gilead Sciences, Inc. | $193B | -61.2 | -20.6 | -3.4 | -134.5 | 5.5 | 5 | BULLISH | 32.4 |
| LLY Eli Lilly and Company | $1.2T | 42.9 | 102.4 | 39.2 | 30.9 | 49.6 | 9 | BULLISH | 55.5 |
| AMGN Amgen Inc. | $237B | 27.6 | 91.5 | 19.5 | 23.6 | 9.2 | 8 | BULLISH | 57.8 |
| GSK GSK plc | $102B | 16.0 | 25.5 | 18.8 | 5.2 | 5.0 | 7 | BULLISH | 18.9 |
| AZN AstraZeneca PLC | $266B | 25.4 | 22.0 | 15.0 | 16.3 | 8.6 | 9 | LEAN BULL | 4.5 |
| BMY Bristol-Myers Squibb Company | $126B | 13.6 | 46.7 | 17.8 | 25.6 | 3.1 | 8 | LEAN BULL | 46.8 |
| NONOF Novo Nordisk A/S | $172B | 9.9 | 59.8 | 35.2 | 26.7 | 5.6 | 5 | NEUTRAL | -28.1 |
| MRK Merck & Co., Inc. | $358B | 112.6 | 7.0 | 6.1 | -8.0 | 4.5 | 4 | BEARISH | 63.5 |
| NVS Novartis AG | $287B | 23.6 | 30.6 | 16.8 | 22.7 | 0.8 | 5 | BULLISH | 20.3 |
| TMO Thermo Fisher Scientific Inc. | $249B | 36.5 | 13.4 | 8.6 | 14.2 | 8.3 | 8 | BULLISH | 21.2 |
| SRTOY Sartorius Stedim Biotech S.A. | $228B | 66.4 | 7.4 | 6.2 | 12.5 | 4.4 | 8 | BULLISH | -0.5 |
| UNH UnitedHealth Group Incorporated | $375B | 23.4 | 15.9 | 13.5 | 3.6 | 3.3 | 7 | BULLISH | 14.0 |
| NVS Novartis AG | $287B | 23.6 | 30.6 | 16.8 | 22.7 | 0.8 | 5 | BULLISH | 20.3 |
| ABBV AbbVie Inc. | $505B | 80.7 | -206.4 | 23.5 | 21.3 | 10.4 | 7 | BULLISH | 25.6 |
| JNJ Johnson & Johnson | $636B | 40.7 | 20.0 | 21.3 | 0.8 | 7.8 | 6 | BULLISH | 42.0 |
| TMO Thermo Fisher Scientific Inc. | $249B | 36.5 | 13.4 | 8.6 | 14.2 | 8.3 | 8 | BULLISH | 21.2 |
| SNY Sanofi | $100B | 23.0 | 5.7 | 6.4 | 2.8 | 13.4 | 6 | BULLISH | -18.9 |
| PFE Pfizer Inc. | $171B | 39.4 | 5.0 | 11.3 | -1.6 | -0.2 | 7 | BULLISH | 22.5 |
| RHHBF Roche Holding AG | $393B | 26.0 | 40.2 | 24.6 | 22.6 | 27.8 | 6 | BULLISH | 30.5 |
| GILD Gilead Sciences, Inc. | $193B | -61.2 | -20.6 | -3.4 | -134.5 | 5.5 | 5 | BULLISH | 32.4 |
| LLY Eli Lilly and Company | $1.2T | 42.9 | 102.4 | 39.2 | 30.9 | 49.6 | 9 | BULLISH | 55.5 |
| AMGN Amgen Inc. | $237B | 27.6 | 91.5 | 19.5 | 23.6 | 9.2 | 8 | BULLISH | 57.8 |
| GSK GSK plc | $102B | 16.0 | 25.5 | 18.8 | 5.2 | 5.0 | 7 | BULLISH | 18.9 |
| SRTOY Sartorius Stedim Biotech S.A. | $228B | 66.4 | 7.4 | 6.2 | 12.5 | 4.4 | 8 | BULLISH | -0.5 |
| UNH UnitedHealth Group Incorporated | $375B | 23.4 | 15.9 | 13.5 | 3.6 | 3.3 | 7 | BULLISH | 14.0 |
| AZN AstraZeneca PLC | $266B | 25.4 | 22.0 | 15.0 | 16.3 | 8.6 | 9 | LEAN BULL | 4.5 |
| BMY Bristol-Myers Squibb Company | $126B | 13.6 | 46.7 | 17.8 | 25.6 | 3.1 | 8 | LEAN BULL | 46.8 |
| NONOF Novo Nordisk A/S | $172B | 9.9 | 59.8 | 35.2 | 26.7 | 5.6 | 5 | NEUTRAL | -28.1 |
| MRK Merck & Co., Inc. | $358B | 112.6 | 7.0 | 6.1 | -8.0 | 4.5 | 4 | BEARISH | 63.5 |
Profile Radar
Valuation vs Profitability
Performance Comparison
Industry Market Share
NVS vs Benchmarks
ROIC
Gross Margin
Op Margin
Net Margin
Revenue Growth
P/E Ratio
ROE
Piotroski F